NCT06050109View on ClinicalTrials.gov

The Benefits of Continued Use of Ovarian Function Suppression After 5 Years

RecruitingOBSERVATIONAL
Enrollment

1,200

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 1, 2028

Study Completion Date

September 1, 2028

Conditions
Breast Cancer FemaleEndocrine Therapy
Interventions
DRUG

OFS continues to use group after 5 years use

Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.

DIAGNOSTIC_TEST

Immunohistochemical detection of HR status

Enrolled patients must be HR-positive premenopausal breast cancer patients

Trial Locations (1)

Unknown

RECRUITING

Wu Xinhong, Wuhan

All Listed Sponsors
lead

Hongmei Zheng, PhD

OTHER